ERBB2 and breast cancer: As the basis for our current study, the breast cancer preventative capacity of the FGFR1-3 inhibitor AZD4547 remains unclear in individuals who are at-risk for ErbB2-overexpressing breast cancer development due to factors such as: genetics, familial history of breast cancer, personal history of breast cancer, dense mammary tissues, environmental exposures, and lifestyle.